Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVOG8A)

• Drug Name: Pemvidutide Drug Info
• Synonyms: Pemvidutide; ALT801; GLXC-26955; 2538014-94-5

Indication

Disease Entry	ICD 11	Status	REF
Obesity	5B81	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 167312391
  TTD Drug ID: DMVOG8A

Molecule-Related Drug Atlas

Drug(s) Targeting Glucagon-like peptide 1 receptor (GLP1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Semaglutide	DMAGFOD	Type-2 diabetes	5A11	Approved	[3]
Liraglutide	DM3FXPS	Non-insulin dependent diabetes	5A11	Approved	[4]
Exenatide	DMYHBKN	Inflammation	1A00-CA43.1	Approved	[5]
Dulaglutide	DMYXBV3	Type-2 diabetes	5A11	Approved	[6]
Lixisenatide	DM0QJDC	Type-2 diabetes	5A11	Approved	[7]
Pramlintide	DM0EZ9Q	Type-1/2 diabetes	5A10-5A11	Approved	[4]
Albiglutide	DM1JEGF	Type-2 diabetes	5A11	Approved	[7]
Tirzepatide	DMQNMAT	Type 2 diabetes	5A11	Approved	[8]
Efpeglenatide	DMKA2PI	Type-2 diabetes	5A11	Phase 3	[9]
GLP-1	DMR6YH3	Diabetic complication	5A2Y	Phase 3	[3]

Drug(s) Targeting Glucagon receptor (GCGR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glucagon recombinant	DMFLUTR	Hypoglycemia	5A41	Approved	[10]
Dasiglucagon	DM74SVE	Hypoglycemia	5A41	Approved	[11]
Retatrutide	DM8WU0Q	Obesity	5B81	Phase 3	[12]
MK-8521	DMVNAYE	Type-2 diabetes	5A11	Phase 2	[9]
LY2944876	DML6XWR	Diabetic complication	5A2Y	Phase 2	[13]
TT-401	DMRQ0SA	Type-2 diabetes	5A11	Phase 2	[9]
LGD-6972	DMPL9KG	Type-2 diabetes	5A11	Phase 2	[14]
PF-06291874	DMN94QM	Type-2 diabetes	5A11	Phase 2	[15]
LY-2409021	DMZOIP4	Type-2 diabetes	5A11	Phase 2	[16]
REMD 477	DM13OVF	Type-1 diabetes	5A10	Phase 2	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucagon receptor (GCGR)	TT9O6WS	GLR_HUMAN	Agonist	[2]
Glucagon-like peptide 1 receptor (GLP1R)	TTVIMDE	GLP1R_HUMAN	Agonist	[2]

References

• [1] ClinicalTrials.gov (NCT05292911) A 12-Week Extension Study of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD). U.S.National Institutes of Health.
• [2] Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis. Sci Rep. 2022 Apr 23;12(1):6666.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
• [4] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [5] Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes TechnolTher. 2009 Jun;11(6):353-9.
• [6] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [7] GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42.
• [8] Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021 Jan 23;106(2):388-396.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Glucagon receptor expression and glucagon stimulation of ghrelin secretion in rat stomach. Biochem Biophys Res Commun. 2007 Jun 15;357(4):865-70.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [12] Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert Opin Investig Drugs. 2023 May;32(5):355-359.
• [13] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [14] Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
• [15] Clinical pipeline report, company report or official report of pfizer.
• [16] Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obes Metab. 2015 Apr;17(4):414-22.
• [17] Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2018 May;20(5):1302-1305.